Risk stratification in Waldenström macroglobulinemia
- 10 January 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Hematology
- Vol. 5 (2), 187-199
- https://doi.org/10.1586/ehm.11.82
Abstract
Waldenström macroglobulinemia is characterized by the production of serum monoclonal IgM and lymphoplasmacytic bone marrow infiltration. At least 25% of patients are asymptomatic at diagnosis and treatment is only mandatory in cases of symptomatic disease. Beside reports on treatment results, reviewing risk assessment is another way to describe the clinical course of the disease. This information may be particularly useful when numerous treatment options are available. While the introduction of new treatment approaches reinforces the need for careful risk assessment, the identification of useful prognostic information requires prolonged follow-up in patients who have not been treated with current therapeutic options. This limitation should be taken into account when using and interpreting available prognostic information, especially survival estimates.Keywords
This publication has 65 references indexed in Scilit:
- Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2011
- International prognostic scoring system for Waldenström macroglobulinemiaBlood, 2009
- Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemiaBritish Journal of Haematology, 2006
- Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s MacroglobulinemiaJournal of Clinical Oncology, 2005
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 casesBritish Journal of Haematology, 2001
- Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)Blood, 2001
- Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utilityBlood, 1994
- Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.Journal of Clinical Oncology, 1993